Acute Migraine Study

Adults 18 to 75 years of age may qualify for a research study evaluating an investigational medication for migraine attacks.

About the Study

Migraine is a neurological condition that can cause severe headaches, nausea, sensitivity to light and sound, and disruption of daily activities.

This research study is evaluating an investigational medication called Elismetrep (K-304) for the acute treatment of migraine. Researchers are studying the safety and effectiveness of Elismetrep in adults who experience migraine with or without aura.

Participants will be randomly assigned to receive either investigational study medication or placebo. The study is double-blind, meaning neither participants nor most study staff will know which treatment is assigned during the study.

Participation may last up to approximately 81 days, including screening, treatment, and follow-up assessments.

Qualifications

You may be able to join if you:

• Are 18 to 75 years of age
• Have a history of migraine with or without aura for at least one year
• Experience migraine attacks on a recurring basis
• Are willing to use an electronic diary on your own smartphone device during the study
• Are willing to treat one qualifying migraine attack with study medication
• Are willing to attend study visits and complete study procedures
• Are not currently pregnant or breastfeeding
• Meet additional study eligibility requirements determined by the research team

Fill out the short form to learn more and how you might qualify!